929622-08-2

Basic information

• Product Name: Bavisant
• Synonyms: Bavisant;JNJ 31001074;JNJ31001074;JNJ-31001074
• CAS NO: 929622-08-2
• Molecular Formula: C₁₉H₂₇N₃O₂
• Molecular Weight: 329.43658
• Mol File: 929622-08-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 485.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.220±0.06 g/cm3(Predicted)
• PKA: 7.66±0.70(Predicted)
• CAS DataBase Reference: Bavisant(CAS DataBase Reference)
• NIST Chemistry Reference: Bavisant(929622-08-2)
• EPA Substance Registry System: Bavisant(929622-08-2)

Safety Data

• Hazardous Substances Data: 929622-08-2(Hazardous Substances Data)

Upstream product

• 929622-20-8 (4-morpholin-4-ylmethylphenyl)piperazin-1-yl-methanone 
• 27374-25-0 [(1-Ethoxycyclopropyl)oxy]trimethylsilane 
• 77278-34-3 4-cyclopropylpiperazine-1-carboxylic acid tert-butyl ester 
• 929622-18-4 4-(4-formylbenzoyl)piperazine-1-carboxylic acid tert-butyl ester 
• 16173-52-7 4-formylbenzoyl chloride 
• 619-66-9 4-Carboxybenzaldehyde 
• 110-91-8 morpholine 
• 929622-21-9 4-(4-cyclopropyl-piperazine-1-carbonyl)-benzaldehyde 
• 123742-32-5 4-(4-Morpholinylmethyl)benzoyl chloride 

Downstream Products

• 929622-10-6 Bavisant citrate 

Relevant articles and documents

Novel benzamide-based histamine H3 receptor antagonists: The identification of two candidates for clinical development

The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H3 receptor antagonists is described. The compounds described are high affinity histamine H3 antagonists. Optimization of the physical properties of these histamine H3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.

CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR

Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.

NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES

The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor.